Interleukin-28 receptor (IL-28R)

The **Interleukin-28 receptor** (IL-28R or interferon lambda receptor) is a heterodimeric cell surface receptor specifically recognizing type III interferons, including IL-28A, IL-28B, IL-29, and IFN-λ4. The receptor is composed of the IL-28 receptor alpha chain (IFNLR1/IL28RA) and the IL-10 receptor beta chain (IL10RB), the latter being shared with other IL-10 family cytokines[1][2]. Unlike type I interferon receptors, IL-28R is predominantly expressed on epithelial cells and some myeloid cells, confining its potent antiviral, immune-modulating, and anti-proliferative functions to barrier surfaces such as the skin, gut, and respiratory tract. Upon binding of its ligands, the receptor activates JAK-STAT signaling pathways, leading to induction of interferon-stimulated genes that inhibit viral replication and modulate immune responses[2]. It plays a clinically significant role in infection control (especially hepatitis C), host defense at barrier tissues, inflammation, cancer surveillance, and is a target for emerging antiviral therapies. Genetic variation near the IL28B gene is a predictive biomarker for antiviral therapy responsiveness in hepatitis C patients[1]. The receptor is considered a promising therapeutic target with potentially fewer systemic side effects due to its restricted expression compared to type I interferon receptors[2].

Other names

Interleukin-28 receptorIL-28RInterferon lambda receptor (IFNLR)IFNLR1IL28RAtype III interferon receptor

Ligand-induced receptor dimerization (IL-28/29 binding to IL28RA and IL10RB)\nActivation of Janus kinases (JAK1, TYK2, JAK2)\nPhosphorylation of STAT proteins (STAT1, STAT2, STAT3, STAT4, STAT5)\nInduction of interferon-stimulated genes providing antiviral and immune modulatory effects[2]